[Show abstract][Hide abstract] ABSTRACT: The treatment of a brain glioma remains one of the most difficult challenges in oncology. In the present study a delivery system was developed for targeted drug delivery across the blood-brain barrier (BBB) to the brain cancer cells. A cyclic arginine-glycine-aspartic acid (RGD) peptide and transferrin (TF) were utilized as targeting ligands. Cyclic RGD peptides are specific targeting ligands of cancer cells and TFs are ligands that specifically target the BBB and cancer cells. Liposome (LP) was used to conjugate the cyclic RGD and TFs to establish the brain glioma cascade delivery system (RGD/TF-LP). The LPs were prepared by the thin film hydration method and physicochemical characterization was conducted. In vitro cell uptake and three-dimensional tumor spheroid penetration studies demonstrated that the system could target endothelial and tumor cells, as well as penetrate the tumor cells to reach the core of the tumor spheroids. The results of the in vivo imaging further demonstrated that the RGD/TF-LP provided the highest brain distribution. As a result, the paclitaxel-loaded RGD/TF-LP presents the best antiproliferative activity against C6 cells and tumor spheroids. In conclusion, the RGD/TF-LP may precisely target brain glioma, which may be valuable for glioma imaging and therapy.
[Show abstract][Hide abstract] ABSTRACT: The aim of this study was to analyze the association between aspirin intake and its effect for chemoprevention of pancreatic cancer incidence by using a meta-analysis method.
The databases of MEDLINE, EMBASE, and Wangfang (Chinese database) were retrieved to identify eligible studies. Odds ratio (OR) and 95% confidence interval (CI) were calculated using a random-effects model.
A total of 10 studies (4 case-control studies, 5 prospective cohort studies, and 1 randomized controlled trial) with 7,252 cases of pancreatic cancer and more than 120,0000 healthy control subjects were enrolled in the studies. Pooled analyses showed that high-dose aspirin intake was marginally associated with decreased risk for pancreatic cancer for overall analysis (OR, 0.88; 95% CI, 0.76-1.01) as well as for both cohort and case-control studies (OR, 0.70; 95% CI, 0.54-1.16, for the cohort studies; OR, 0.82; 95% CI, 0.62-1.02, for the case-control studies), without between-study heterogeneity. Stratified analysis for Americans showed a similar result (OR, 0.82; 95% CI, 0.65-1.02). In contrast, our study inferred that low-dose aspirin intake was not associated with risk for pancreatic cancer for the total and subgroup analyses.
In summary, our study indicated that high-dose aspirin, rather than low-dose aspirin, might be associated with decreased risk for pancreatic cancer, especially for Americans.
[Show abstract][Hide abstract] ABSTRACT: Many epidemiological studies have studied the associations between adiponectin rs1501299G/T, rs822395A/C, and rs822396A/G polymorphisms and risk of cancer development, while conflicting results have been reported. Therefore, we conducted a meta-analysis to assess the associations. We retrieved the following databases: Medline, Embase, Web of Science, and Wanfang, and the latest update date was 15th of August 2012. Odds ratio (OR) and corresponding 95 % confidence interval (95 % CI) were calculated by using fixed- or random-effect model. Overall, there were 13 case-control studies consisting of 7,902 subjects for adiponectin rs1501299G/T, seven studies consisting of 6,209 subjects for rs822395A/C, and seven studies consisting of 5,791 subjects for rs822396A/G polymorphism in this study. Combined analyses indicated that neither adiponectin rs822395A/C nor rs822396A/G was associated with risk of cancer incidence (OR (95 % CI) 0.91 (0.77–1.77), P
z test = 0.26 for CC vs. AA and 0.96 (0.87–1.05) for C carriers vs. A carriers, P
z test = 0.33 for rs822395A/C; 0.88 (0.53–1.47) for GG vs. AA, P
z test = 0.63 and 0.94 (0.84–1.04) for G carriers vs. A carriers, P
z test = 0.24 for rs822396A/G polymorphism). Similarly, combined analysis also indicated that adiponectin rs1501299G/T polymorphism was not associated with risk of cancer development (OR (95 % CI) 0.86 (0.73–1.01) for TT vs. GG, P
z test = 0.07 and 1.17 (0.98–1.39), P
z test = 0.08). However, when stratified analyses were conducted, the result indicated that T allele was significantly associated with increased cancer risk for Caucasians (OR (95 % CI) 1.28 (1.06–1.64) and P
z test = 0.01 for G carriers vs. T carriers) and associated with increased risk of colorectal cancer development while with decreased risk of prostate cancer incidence compared to G allele (OR (95 % CI) 1.34 (1.14–1.57), P
z test < 0.01 for G carriers vs. T carriers for colorectal cancer; 0.80 (0.65–0.97), P
z test = 0.03 for TG vs. GG for prostate cancer). In summary, this meta-analysis indicated that adiponectin rs1501299G/T, rather than rs822395A/C and rs822396A/G polymorphism, was associated with risk of cancer development, especially for colorectal and prostate cancer.
[Show abstract][Hide abstract] ABSTRACT: To explore the roles and mechanisms of E2F-1 and PAC1 in signaling apoptosis of Saos-2 cells under oxidative stress.
siRNAs were used to construct the cell clones of expressing siE2F-1 and siPAC1. E2F-1/PAC1-mediated induction of apoptotic cell death in response to H2O2 were examined by trypan blue exclusion and the expression levels of related target factors detected by Western blot.
The cell viabilities of Saos-2/siE2F-1 and Saos-2/siPAC1 increased markedly comparing with the control cells after the treatment of H2O2. And the expression level of p-ERK1/2 was higher than that of the control cells.
The pathway of E2F-1/PAC1/MAPKase is a specific cascade for apoptotic signaling.
No preview · Article · May 2012 · Zhonghua yi xue za zhi